Recent Posts
The IN VIVO Blog
Return To Blog Listing
News, insight and analysis on the business of the biopharmaceutical industry from the editors of Windhover Information and FDC Reports, publishers of IN VIVO and "The Pink Sheet".
Recent Posts Tagged With 'nice'
"We\'re Not Like NICE," Barks Germany\'s IQWiG
It's not as if the UK's cost-effectiveness watchdog NICE isn't used to a bit of bashing. Patient groups, spurned companies, disease foundations, the good 'ole British public have all had a go over the decade or so since this fourth hurdle came into b...
What\'s the Hardest Job in the Biopharma World?
Maybe it's yours. Maybe it's Jeff Kindler's (keep Pfizer small? Yeah right.) Maybe it's Elan CEO Kelly Martin's(all those shenanigans with Biogen over the J&J Alzheimer deal, ouch).Most likely, though, it's Andrew Dillon's--he, in case you forgot...
NICE and the Definition of Innovation
What 'innovation' means to NICE--or at least, how it takes innovation into account in its cost-effectiveness assessments--may yet become a little clearer. Tomorrow the National Institute of Clinical Excellence will hold one of its regular public boar...
Regulators and Cost Watchdogs Getting Too Close, says EMEA's Lonngren
The European regulatory agency, EMEA, and Europe's various cost-effectiveness watchdogs are brushing up a little too close for comfort, according to Thomas Lonngren, EMEA's executive director. "The decision points for approval [of a medicine] and its...
The NICE Report: A Curate's Egg?
We promised we'd come back to it. Several industry representatives have classified Sir Ian Kennedy's report into NICE's value-assessment methodologies as 'a curate's egg', suggesting something that's part good, part bad...but pretty much spoiled as a...
NICE Should Keep QALY
As anticipated, Sir Ian Kennedy's report into whether NICE values innovation appropriately (read: sufficiently broadly to satisfy the industry) has been published. This matters, remember, because NICE's methodologies, priorities and direction are and...
Have a NICE Day: Look out for Report on Value-Assessment
Keep your eyes peeled for item number 6 on the agenda for NICE’s AGM, which kicks off today at 2pm BST. It’s “to receive Sir Ian Kennedy’s report: ‘Appraising the value of innovation & other benefits—a short study for NICE.’A short ...
Stuck at NICE? Flash your Innovation Pass
Well, you will be able to soon, anyway. The Innovation Pass was a top action item within the UK government’s new Life Sciences Blueprint, unveiled at Imperial College Business Center in London today.The Blueprint’s lofty goals include turning the...
